FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

@article{Liu2008FTY720DP,
  title={FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.},
  author={Qing Liu and Xiaobin Zhao and Frank W. Frissora and Yihui Ma and Ramasamy Santhanam and David Jarjoura and Amy G Lehman and Danilo Perrotti and C Chen and James T Dalton and Natarajan Muthusamy and John C. Byrd},
  journal={Blood},
  year={2008},
  volume={111 1},
  pages={275-84}
}
FTY720 is an immunosuppressant developed to prevent organ transplant rejection. Recent studies indicate an additional role for FTY720 in inducing cell apoptosis. We demonstrate here that FTY720 mediates toxic effects in cell lines representing different B-cell malignancies and primary B cells from patients with chronic lymphocytic leukemia (CLL). In… CONTINUE READING